Journal article · 2020 · Open access
Regulation, innovation and disruption: the European Medicines Agency and adaptive licensing of pharmaceuticals
Law Innovation and Technology, 12(2), 259–283 · Published 2 July 2020 · DOI 10.1080/17579961.2020.1815406
In brief
“Regulation, innovation and disruption: the European Medicines Agency and adaptive licensing of pharmaceuticals” is a 2020 journal article by Keith Syrett, published in Law Innovation and Technology. OpenAlex counts 10 citations as of 19 November 2026. It is open access: the full text is free to read at Explore Bristol Research.
- Citations
- 10
- Most cited in
- 2026 (4)
- Field-weighted impact
- 0.69
- References
- 1
- Authors
- 1
Abstract
Growing concerns over the related problems of speedily bringing innovative pharmaceuticals (especially so-called precision medicines) to market, and addressing areas of unmet medical need, have engendered critical scrutiny of the existing process for the licensing of pharmaceutical products. The objective is to enable these products to receive approval sooner, but on the basis of the provision of less complete evidence, than was previously the case. This article examines the attempts made to tackle this issue at European Union level, through a pilot programme exploring ‘adaptive’ approaches to licensing operated by the European Medicines Agency. Responses to this initiative indicate significant difficulty in securing regulatory legitimacy in this context. This suggests that innovative pharmaceutical technologies are disruptive of existing regulatory frameworks, such that future attempts to accommodate them within these may be susceptible to failure.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Syrett, K. (2020). Regulation, innovation and disruption: the European Medicines Agency and adaptive licensing of pharmaceuticals. Law Innovation and Technology, 12(2), 259–283. https://doi.org/10.1080/17579961.2020.1815406
MLA 9
Syrett, Keith. “Regulation, innovation and disruption: the European Medicines Agency and adaptive licensing of pharmaceuticals.” Law Innovation and Technology, vol. 12, no. 2, 2020, pp. 259–283. https://doi.org/10.1080/17579961.2020.1815406.
Chicago
Syrett, Keith. 2020. “Regulation, innovation and disruption: the European Medicines Agency and adaptive licensing of pharmaceuticals.” Law Innovation and Technology 12 (2): 259–283. https://doi.org/10.1080/17579961.2020.1815406.
Harvard
Syrett, K. (2020) ‘Regulation, innovation and disruption: the European Medicines Agency and adaptive licensing of pharmaceuticals’, Law Innovation and Technology, 12(2), pp. 259–283. doi:10.1080/17579961.2020.1815406.
IEEE
K. Syrett, “Regulation, innovation and disruption: the European Medicines Agency and adaptive licensing of pharmaceuticals,” Law Innovation and Technology, vol. 12, no. 2, pp. 259–283, 2020, doi: 10.1080/17579961.2020.1815406.
BibTeX
@article{syrett2020regulation,
title = {{Regulation, innovation and disruption: the European Medicines Agency and adaptive licensing of pharmaceuticals}},
author = {Syrett, Keith},
journal = {Law Innovation and Technology},
year = {2020},
volume = {12},
number = {2},
pages = {259--283},
doi = {10.1080/17579961.2020.1815406},
url = {https://doi.org/10.1080/17579961.2020.1815406}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2021 | 1 | |
| 2022 | 1 | |
| 2023 | 1 | |
| 2024 | 1 | |
| 2025 | 2 | |
| 2026 | 4 |
Its field-weighted citation impact is 0.69: it has been cited 0.69 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- European Medicines Agency
- drug regulation
- precision medicine
- regulatory legitimacy
- unmet medical needs
- accelerated approval
- pilot project
- European Union health policy
Work with this paper
Most-cited papers in Nursing
- Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled StudyÖmer Toprak, Hüseyin Kurt, Yasin Sarı and 3 more · Kidney & Blood Pressure Research · 2017 · 29,772 citations
- The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm InfantsElda Dermyshi, Yizhong Wang, Chongbing Yan and 4 more · Neonatology · 2017 · 24,587 citations
- Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.Donald E. Paglia, William N. Valentine · PubMed · 1967 · 10,901 citations
- Maternal and child undernutrition and overweight in low-income and middle-income countriesRobert E. Black, Cesar Gomes Victora, Susan P. Walker and 8 more · The Lancet · 2013 · 9,505 citations
- The content validity index: Are you sure you know what's being reported? critique and recommendationsDenise F. Polit, Cheryl Tatano Beck · Research in Nursing & Health · 2006 · 8,193 citations
Questions about this paper
How do I cite this paper in APA style?
Syrett, K. (2020). Regulation, innovation and disruption: the European Medicines Agency and adaptive licensing of pharmaceuticals. Law Innovation and Technology, 12(2), 259–283. https://doi.org/10.1080/17579961.2020.1815406
How many times has this paper been cited?
10 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Explore Bristol Research: sign in and open the full text from this page.
Who wrote this paper?
Keith Syrett.
What is the DOI of this paper?
10.1080/17579961.2020.1815406, permanently at https://doi.org/10.1080/17579961.2020.1815406. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.